直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

IPR and CBM Statistics for Final Written Decisions Issued in June 2015

July 14, 2015

Authored and Edited by Daniel F. Klodowski; Elliot C. Cook; Aaron L. Parker

In the 36 Final Written Decisions issued by the Patent Trial and Appeal Board in June, the Board cancelled 446 (86.27%) of the instituted claims, and it held that 47 (9.09%) of the instituted claims were not proven unpatentable by a preponderance of the evidence.  Patent owners conceded 24 (4.64%) of the instituted claims through motions to amend.

PTAB July

On a per-case basis, no instituted or substitute claims survived in 26 (72.22%) of the decisions, all instituted claims survived in 5 (13.89%) of the decisions, and a mixed outcome occurred in 5 (13.89%) of the decisions.  A mixed outcome occurs where at least one instituted or substitute claim remains patentable, and at least one is cancelled, in a Board decision.

PTAB July_2

More detailed cumulative statistics on the Board’s IPR and CBM decisions, updated through July 1, 2015, are available here on the AIA Blog.

Contacts

Daniel F. Klodowski
Partner
Washington, DC
+1 202 408 4216
Email
Elliot C. Cook
Partner
Reston, VA
+1 571 203 2738
Email
Aaron L. Parker
Partner
Washington, DC
+1 202 408 4387
Email

Copyright © 2015 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. Additional disclaimer information. 

Related Insights

Conference

IP Life Sciences Forum 2026

December 13-15, 2026

Coral Gables

Panel Discussion

2026 Advanced Patent Law Institute

December 3-4, 2026

Stanford

Conference

2026 TIPA International Symposium

October 30, 2026

Taipei City

Conference

4th Global Patent Litigation FORUM

October 29, 2026

Munich

Hybrid Conference

Intellectual Property Law Institute 2026 – California

October 19-20, 2026

San Francisco

Conference

2nd Annual Forum on Pharma & Biotech Patent Litigation USA & Canada

October 14-16, 2026

New York

Seminar

PTAB Bar Association Thought Leader Summit 2026

October 7, 2026

Alexandria

Seminar

As Congress Intended: Restoring the ITC’s Statutory Function Through Funding Transparency and Substantive Reforms

October 1, 2026

Washington, DC

Articles

D. Mass. Patent Litigation Update, March 2026

D. Mass. Patent Litigation Update: August 2026

September 29, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP